Curcumin: A Naturally Occurring Modulator of Adipokines in Diabetes

Journal of Cellular Biochemistry

Volumn 118, Issue 12, 2017, Pages 4170-4182

  Hajavi, Jafar ^a   Momtazi, Amir Abbas ^b   Johnston, Thomas P ^c   Banach, Maciej ^d   Majeed, Muhammed ^e   Sahebkar, Amirhossein ^f,g  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e SABINSA CORPORATION   (United States)

^f MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ADIPOKINES; BLOOD GLUCOSE; CURCUMIN; DIABETES; INSULIN RESISTANCE

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CURCUMIN; INTERLEUKIN 6; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; TUMOR NECROSIS FACTOR; CYTOKINE;

ADIPOCYTE; ARTICLE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DRUG EFFECT; DRUG SAFETY; DRUG STRUCTURE; HUMAN; INSULIN RESISTANCE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DIABETIC COMPLICATION; FEMALE; GENETICS; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADIPOKINES; ANIMALS; CURCUMIN; CYTOKINES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; MALE;

EID: 85031816960     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.26121     Document Type: Article

References (181)

1. Abbas Momtazi A, Sahebkar A. 2016. Difluorinated curcumin: a promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile. Curr Pharm Des 22:4386–4397.
2. Abdollahi E, Momtazi AA, Johnston TP, Sahebkar A. 2017. Therapeutic effects of curcumin in inflammatory and immune-mediated diseases: A nature-made jack-of-all-trades? J Cell Physiol. https://doi.org/10.1002/jcp.25778
3. Arun N, Nalini N. 2002. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum Nutr 57:41–52.
4. Aziz MTA, El-Asmar MF, El-Ibrashy IN, Rezq AM, Al-Malki AL, Wassef MA, Fouad HH, Ahmed HH, Taha FM, Hassouna AA. 2012. Effect of novel water soluble curcumin derivative on experimental type-1 diabetes mellitus (short term study). Diabetol Metab Syndr 4:1.
5. Bacha F, Saad R, Gungor N, Arslanian SA. 2004. Adiponectin in youth relationship to visceral adiposity, insulin sensitivity, and β-cell function. Diabetes Care 27:547–552.
6. Bai Y-n, Zheng J, Song Z-f, Du Y, Wen Y. 2013. Effect of curcumin on expression of adiponectin in mice with insulin resistance [J]. J Shanghai Jiaotong Univ (Medical Science) 2:003.
7. Bailey SD, Loredo-Osti JC, Lepage P, Faith J, Fontaine J, Desbiens KM, Hudson TJ, Bouchard C, Gaudet D, Pérusse L. 2006. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 55:2896–2902.
8. Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajala MW, Pocai A, Scherer PE. 2004. Regulation of fasted blood glucose by resistin. Science 303:1195–1198.
9. Bates SH, Kulkarni RN, Seifert M, Myers MG. 2005. Roles for leptin receptor/STAT3-dependent and-independent signals in the regulation of glucose homeostasis. Cell Metab 1:169–178.
10. Bates SH, Myers MG. 2003. The role of leptin receptor signaling in feeding and neuroendocrine function. Trends Endocrinol Metab 14:447–452.
11. Beckers S, Peeters AV, Freitas F, Mertens IL, Hendrickx JJ, Gaal LF, Hul W. 2008. Analysis of genetic variations in the resistin gene shows no associations with obesity in women. Obesity 16:905–907.
12. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953.
13. Berg AH, Lin Y, Lisanti MP, Scherer PE. 2004. Adipocyte differentiation induces dynamic changes in NF-κB expression and activity. Am J Physiol Endocrinol Metab 287:E1178–E1188.
14. Blüher M, Brennan AM, Kelesidis T, Kratzsch J, Fasshauer M, Kralisch S, Williams CJ, Mantzoros CS. 2007. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program comparative evaluation of three assays. Diabetes Care 30:280–285.
15. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. 2005. Resistin, an adipokine with potent proinflammatory properties. J Immunol 174:5789–5795.
16. Castro C, Barcala Tabarrozzi A, Winnewisser J, Gimeno M, Antunica Noguerol M, Liberman A, Paz D, Dewey R, Perone M. 2014. Curcumin ameliorates autoimmune diabetes. Evidence in accelerated murine models of type 1 diabetes. Clin Exp Immunol 177:149–160.
17. Chen C-C, Li T-C, Li C-I, Liu C-S, Wang H-J, Lin C-C. 2005. Serum resistin level among healthy subjects: Relationship to anthropometric and metabolic parameters. Metabolism 54:471–475.
18. Chen M-P, Chung F-M, Chang D-M, Tsai JC-R, Huang H-F, Shin S-J, Lee Y-J. 2006. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91:295–299.
19. Cheng A-L, Hsu C-H, Lin J-K, Hsu M-M, Ho Y-F, Shen T-S, Ko J-Y, Lin J-T, Lin B-R, Ming-Shiang W. 2001. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21:2895–2900.
20. Chougala MB, Bhaskar JJ, Rajan MGR, Salimath PV. 2012. Effect of curcumin and quercetin on lysosomal enzyme activities in streptozotocin-induced diabetic rats. Clin Nutr 31:749–755.
21. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. 2012. Curcumin extract for prevention of type 2 diabetes. Diabetes Care 35:2121–2127.
22. Chuengsamarn S, Rattanamongkolgul S, Phonrat B, Tungtrongchitr R, Jirawatnotai S. 2014a. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: A randomized controlled trial. J Nutr Biochem 25:144–150.
23. Chuengsamarn S, Rattanamongkolgul S, Phonrat B, Tungtrongchitr R, Jirawatnotai S. 2014b. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: A randomized controlled trial. J Nutr Biochem 25:144–150.
24. Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, Rajala MW, Parlow AF, Cheeseboro L. 2004. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145:367–383.
25. Combs TP, Wagner JA, Berger J, Doebber T, Wang W-J, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB. 2002. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: A potential mechanism of insulin sensitization. Endocrinology 143:998–1007.
26. Coppari R, Ichinose M, Lee CE, Pullen AE, Kenny CD, McGovern RA, Tang V, Liu SM, Ludwig T, Chua SC. 2005. The hypothalamic arcuate nucleus: A key site for mediating leptin's effects on glucose homeostasis and locomotor activity. Cell Metab 1:63–72.
27. Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, Yamaguchi H, Ohnuma H, Igarashi M, Tominaga M, Kato T. 2003. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population The Funagata study. Diabetes Care 26:2015–2020.
28. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV. 2003. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 88:5452–5455.
29. Derosa G, Maffioli P, Simental-Mendia LE, Bo S, Sahebkar A. 2016. Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 111:394–404.
30. Di Raimo T, Azzara G, Corsi M, Cipollone D, Vasco VRL, Businaro R. 2015. Adipokines and their involvement as a target of new drugs. J Pharmacovigil 3.
31. Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, Hoogeveen RC, Heiss G. 2004. Adiponectin and the development of type 2 diabetes the atherosclerosis risk in communities study. Diabetes 53:2473–2478.
32. Ebihara K, Ogawa Y, Masuzaki H, Shintani M, Miyanaga F, Aizawa-Abe M, Hayashi T, Hosoda K, Inoue G, Yoshimasa Y. 2001. Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 50:1440–1448.
33. El-Azab MF, Attia FM, El-Mowafy AM. 2011. Novel role of curcumin combined with bone marrow transplantation in reversing experimental diabetes: Effects on pancreatic islet regeneration, oxidative stress, and inflammatory cytokines. Eur J Pharmacol 658:41–48.
34. El-Moselhy MA, Taye A, Sharkawi SS, El-Sisi SFI, Ahmed AF. 2011. The antihyperglycemic effect of curcumin in high fat diet fed rats. Role of TNF-α and free fatty acids. Food Chem Toxicol 49:1129–1140.
35. Elmquist JK, Elias CF, Saper CB. 1999. From lesions to leptin: Hypothalamic control of food intake and body weight. Neuron 22:221–232.
36. Esmaily H, Sahebkar A, Iranshahi M, Ganjali S, Mohammadi A, Ferns G, Ghayour-Mobarhan M. 2015. An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial. Chin J Integr Med 21:332–338.
37. Fantuzzi G. 2005. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115:911–919.
38. Filippatos T, Derdemezis C, Gazi I, Lagos K, Kiortsis D, Tselepis A, Elisaf M. 2008. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 38:71–72.
39. Friedman JM. 2011. Leptin and the regulation of body weigh. Keio J Med 60:1–9.
40. Friedman JM, Halaas JL. 1998. Leptin and the regulation of body weight in mammals. Nature 395:763–770.
41. Friedman SL. 2008. Mechanisms of hepatic fibrogenesis. Gastroenterology 134:1655–1669.
42. Friedman SL, Rockey DC, McGuire RF, Maher JJ, Boyles JK, Yamasaki G. 1992. Isolated hepatic lipocytes and Kupffer cells from normal human liver: Morphological and functional characteristics in primary culture. Hepatology 15:234–243.
43. Fruebis J, Tsao T-S, Javorschi S, Ebbets-Reed D, Erickson MRS, Yen FT, Bihain BE, Lodish HF. 2001. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005–2010.
44. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H. 2005. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 307:426–430.
45. Ganjali S, Blesso CN, Banach M, Pirro M, Majeed M, Sahebkar A. 2017. Effects of curcumin on HDL functionality. Pharmacol Res 119:208–218.
46. Ganjali S, Sahebkar A, Mahdipour E, Jamialahmadi K, Torabi S, Akhlaghi S. 2014. Investigation of the effects of curcumin on serum cytokines in obese individuals: A randomized controlled trial. ScientificWorldJournal. https://doi.org/10.1155/2014/898361
47. Gerber M, Boettner A, Seidel B, Lammert A, Bar J, Schuster E, Thiery J, Kiess W, Kratzsch J. 2005. Serum resistin levels of obese and lean children and adolescents: Biochemical analysis and clinical relevance. J Clini Endocrinol Metab 90:4503–4509.
48. Ghandadi M, Sahebkar A. 2017. Curcumin: An effective inhibitor of interleukin-6. Curr Pharm Des 23:921–931.
49. Ghosh S, Banerjee S, Sil PC. 2015. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update. Food Chem Toxicol 83:111–124.
50. Gonzales AM, Orlando RA. 2008. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutr Metab 5. https://doi.org/10.1186/1743-7075-5-17
51. Haas B, Schlinkert P, Mayer P, Eckstein N. 2012. Targeting adipose tissue. Diabetol Metab Syndr 4:1.
52. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. 2006. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 91:1578–1581.
53. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, Imai Y, Nagai R, Kadowaki T. 2006. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29:1357–1362.
54. Heilbronn L, Rood J, Janderova L, Albu J, Kelley D, Ravussin E, Smith S. 2004. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 89:1844–1848.
55. Hivert M-F, Sullivan LM, Fox CS, Nathan DM, D'Agostino RB, Sr., Wilson PW, Meigs JB. 2008. Associations of adiponectin, resistin, and tumor necrosis factor-α with insulin resistance. J Clin Endocrinol Metab 93:3165–3172.
56. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM. 2011. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17:55–63.
57. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K. 2000. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599.
58. Ismail N, Ragab S, Abd El Baky A, Hamed N, Ibrahim A. 2014a. Effect of oral curcumin administration on insulin resistance, serum resistin and fetuin-A in obese children: randomized placebo-controlled study. Res J Pharm Biol Chem Sci 5:887–896.
59. Ismail NA, Abd El Dayem SM, Salama E, Ragab S, El Baky AN, Ezzat WM. 2016. Impact of curcumin intake on gluco-insulin homeostasis, leptin and adiponectin in obese subjects. Res J Pharm Biol Chem Sci 7:1891–1897.
60. Ismail NA, Ragab S, Abd El Baky ANE, Hamed M, Ibrahim ASA. 2014b. Effect of oral curcumin administration on insulin resistance, serum resistin and fetuin-A in obese children: Randomized placebo-controlled study. Res J Pharm Biol Chem Sci 5:887–896.
61. Jang EM, Choi MS, Jung UJ, Kim MJ, Kim HJ, Jeon SM, Shin SK, Seong CN, Lee MK. 2008. Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters. Metabolism 57:1576–1583.
62. Kabir F, Jahan FA, Khan I, Faruque MO, Hassan Z, Ali L. 2015. Increased concentration of circulating visfatin associates with post-challenged hyperglycaemia and insulin resistance in IGT subjects. J Taibah Univ Med Sci 10:481–487.
63. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. 2006. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784–1792.
64. Kahn BB, Alquier T, Carling D, Hardie DG. 2005. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1:15–25.
65. Karimian MS, Pirro M, Majeed M, Sahebkar A. 2017. Curcumin as a natural regulator of monocyte chemoattractant protein-1. Cytokine Growth Factor Rev 33:55–63.
66. Kaser S, Kaser A, Sandhofer A, Ebenbichler C, Tilg H, Patsch J. 2003. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 309:286–290.
67. Kazazis C, Vallianou NG, Kollas A, Evangelopoulos A. 2014. Curcumin and diabetes: Mechanisms of action and its anti-diabetic properties. Curr Top Nutraceuticals Res 12:135.
68. Kielstein JT, Becker B, Graf S, Brabant G, Haller H, Fliser D. 2003. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 42:62–66.
69. Kim BH, Lee ES, Choi R, Nawaboot J, Lee MY, Lee EY, Kim HS, Chung CH. 2016. Protective effects of curcumin on renal oxidative stress and lipid metabolism in a rat model of type 2 diabetic nephropathy. Yonsei Med J 57:664–673.
70. Kim K-H, Zhao L, Moon Y, Kang C, Sul HS. 2004. Dominant inhibitory adipocyte-specific secretory factor (ADSF)/resistin enhances adipogenesis and improves insulin sensitivity. Proc Natl Acad Sci USA 101:6780–6785.
71. Kisseleva T, Brenner DA. 2006. Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol 21:S84–S87.
72. Klein J, Perwitz N, Kraus D, Fasshauer M. 2006. Adipose tissue as source and target for novel therapies. Trends Endocrinol Metab 17:26–32.
73. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC. 2003. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26:1745–1751.
74. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. 2007. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67:3853–3861.
75. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE. 2006. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6:10.
76. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT. 2006. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 55:249–259.
77. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS. 2003. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 88:4848–4856.
78. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. 2004. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 1:e45.
79. Lelli D, Sahebkar A, Johnston TP, Pedone C. 2017. Curcumin use in pulmonary diseases: State of the art and future perspectives. Pharmacol Res 115:133–148.
80. Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, Li K. 2006. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 114:544–548.
81. Li S, Shin HJ, Ding EL, van Dam RM. 2009. Adiponectin levels and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 302:179–188.
82. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J. 2002. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57–58.
83. Mahesh T, Balasubashini MMS, Menon VP. 2004. Photo-irradiated curcumin supplementation in streptozotocin-induced diabetic rats: Effect on lipid peroxidation. Therapie 59:639–644.
84. Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, Crandall J, Marcovina S, Goldstein B, Goldberg R. 2008. Adiponectin, change in adiponectin, and progression to diabetes in the diabetes prevention program. Diabetes 57:980–986.
85. Matthaei S, Stumvoll M, Kellerer M, Haring HU. 2000. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 21:585–618.
86. Menzaghi C, Trischitta V, Doria A. 2007. Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes 56:1198–1209.
87. Miller RA, Chu Q, Le Lay J, Scherer PE, Ahima RS, Kaestner KH, Foretz M, Viollet B, Birnbaum MJ. 2011. Adiponectin suppresses gluconeogenic gene expression in mouse hepatocytes independent of LKB1-AMPK signaling. J Clin Invest 121:2518–2528.
88. Minokoshi Y, Kim Y-B, Peroni OD, Fryer LG, Müller C, Carling D, Kahn BB. 2002. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415:339–343.
89. Mirzaei H, Naseri G, Rezaee R, Mohammadi M, Banikazemi Z, Mirzaei HR, Salehi H, Peyvandi M, Pawelek JM, Sahebkar A. 2016. Curcumin: A new candidate for melanoma therapy? Int J Cancer 139:1683–1695.
90. Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF, Motomura K, Anania FA, Willson TM, Tsukamoto H. 2000. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275:35715–35722.
91. Mohammadi A, Fazeli B, Taheri M, Sahebkar A, Poursina Z, Vakili V, Yazdi SZ, Keramati Z, Boostani R, Hampson I, Rafatpanah H. 2017. Modulatory effects of curcumin on apoptosis and cytotoxicity-related molecules in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. Biomed Pharmacother 85:457–462.
92. Mohammadi A, Sahebkar A, Iranshahi M, Amini M, Khojasteh R, Ghayour-Mobarhan M, Ferns GA. 2013. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: A randomized crossover trial. Phytother Res 27:374–379.
93. Moon H-S, Dalamaga M, Kim S-Y, Polyzos SA, Hamnvik O-P, Magkos F, Paruthi J, Mantzoros CS. 2013. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev 34:377–412.
94. Morton GJ, Gelling RW, Niswender KD, Morrison CD, Rhodes CJ, Schwartz MW. 2005. Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons. Cell Metab 2:411–420.
95. Murugan P, Pari L. 2007. Influence of tetrahydrocurcumin on erythrocyte membrane bound enzymes and antioxidant status in experimental type 2 diabetic rats. J Ethnopharmacol 113:479–486.
96. Muse ED, Obici S, Bhanot S, Monia BP, McKay RA, Rajala MW, Scherer PE, Rossetti L. 2004. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 114:232–239.
97. Nabavi SF, Thiagarajan R, Rastrelli L, Daglia M, Sobarzo-Sanchez E, Alinezhad H, Nabavi SM. 2015. Curcumin: A natural product for diabetes and its complications. Curr Top Med Chem 15:2445–2455.
98. Nagaev I, Bokarewa M, Tarkowski A, Smith U. 2006. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS ONE 1:e31.
99. Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, Sashida Y, Takahashi K, Kawada T, Nakagawa K. 2005. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem 53:959–963.
100. Noorafshan A, Ashkani-Esfahani S. 2013. A review of therapeutic effects of curcumin. Curr Pharm Des 19:2032–2046.
101. Ochi M, Osawa H, Hirota Y, Hara K, Tabara Y, Tokuyama Y, Shimizu I, Kanatsuka A, Fujii Y, Ohashi J. 2007. Frequency of the G/G genotype of resistin single nucleotide polymorphism at− 420 appears to be increased in younger-onset type 2 diabetes. Diabetes 56:2834–2838.
102. Okamoto M, Ohara-Imaizumi M, Kubota N, Hashimoto S, Eto K, Kanno T, Kubota T, Wakui M, Nagai R, Noda M. 2008. Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration. Diabetologia 51:827–835.
103. Osawa H, Tabara Y, Kawamoto R, Ohashi J, Ochi M, Onuma H, Nishida W, Yamada K, Nakura J, Kohara K. 2007. Plasma resistin, associated with single nucleotide polymorphism −420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population. Diabetes Care 30:1501–1506.
104. Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H, Nishimiya T, Niiya T, Shimizu I, Nishida W. 2004. The G/G genotype of a resistin single-nucleotide polymorphism at −420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet 75:678–686.
105. Pagano C, Soardo G, Pilon C, Milocco C, Basan L, Milan G, Donnini D, Faggian D, Mussap M, Plebani M. 2006. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 91:1081–1086.
106. Panahi Y, Sahebkar A, Amiri M, Davoudi SM, Beiraghdar F, Hoseininejad SL, Kolivand M. 2012a. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: Results of a randomised, double-blind, placebo-controlled trial. Br J Nutr 108:1272–1279.
107. Panahi Y, Sahebkar A, Parvin S, Saadat A. 2012b. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 49:580–588.
108. Panahi Y, Khalili N, Hosseini MS, Abbasinazari M, Sahebkar A. 2014a. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: Results of a randomized controlled trial. Complement Ther Med 22:851–857.
109. Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A. 2014b. Curcuminoid treatment for knee osteoarthritis: A randomized double-blind placebo-controlled trial. Phytother Res 28:1625–1631.
110. Panahi Y, Badeli R, Karami GR, Sahebkar A. 2015a. Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother Res 29:17–21.
111. Panahi Y, Ghanei M, Bashiri S, Hajihashemi A, Sahebkar A. 2015b. Short-term curcuminoid supplementation for chronic pulmonary complications due to sulfur mustard intoxication: Positive results of a randomized double-blind placebo-controlled trial. Drug Res (Stuttg) 65:567–573.
112. Panahi Y, Hosseini MS, Khalili N, Naimi E, Majeed M, Sahebkar A. 2015c. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis. Clin Nutr 34:1101–1108.
113. Panahi Y, Ahmadi Y, Teymouri M, Johnston TP, Sahebkar A. 2016a. Curcumin as a potential candidate for treating hyperlipidemia: A review of cellular and metabolic mechanisms. J Cell Physiol. https://doi.org/10.1002/jcp.25756
114. Panahi Y, Ghanei M, Hajhashemi A, Sahebkar A. 2016b. Effects of curcuminoids-piperine combination on systemic oxidative stress, clinical symptoms and quality of life in subjects with chronic pulmonary complications due to sulfur mustard: A randomized controlled trial. J Diet Suppl 13:93–105.
115. Panahi Y, Hosseini MS, Khalili N, Naimi E, Simental-Mendia LE, Majeed M, Sahebkar A. 2016c. Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. Biomed Pharmacother 82:578–582.
116. Panahi Y, Hosseini MS, Khalili N, Naimi E, Soflaei SS, Majeed M, Sahebkar A. 2016d. Effects of supplementation with curcumin on serum adipokine concentrations: A randomized controlled trial. Nutrition 32:1116–1122.
117. Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendia LE, Sahebkar A. 2016e. Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: A randomized controlled trial. J Cardiovasc Pharmacol 68:223–229.
118. Panahi Y, Alishiri GH, Parvin S, Sahebkar A. 2016c. Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: Results of a randomized controlled trial. J Diet Suppl 13:209–220.
119. Pari L, Murugan P. 2007. Antihyperlipidemic effect of curcumin and tetrahydrocurcumin in experimental type 2 diabetic rats. Ren Fail 29:881–889.
120. Peeyush KT, Gireesh G, Jobin M, Paulose C. 2009. Neuroprotective role of curcumin in the cerebellum of streptozotocin-induced diabetic rats. Life Sci 85:704–710.
121. Perseghin G, Burska A, Lattuada G, Alberti G, Costantino F, Ragogna F, Oggionni S, Scollo A, Terruzzi I, Luzi L. 2006. Increased serum resistin in elite endurance athletes with high insulin sensitivity. Diabetologia 49:1893–1900.
122. Pfützner A, Langenfeld M, Kunt T, Löbig M, Forst T. 2002. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab 49:571–576.
123. Pravenec M, Kazdová L, Landa V, Zídek V, Mlejnek P, Jansa P, Wang J, Qi N, Kurtz TW. 2003. Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat. J Biol Chem 278:45209–45215.
124. Priyanka A, Anusree SS, Nisha VM, Raghu KG. 2014. Curcumin improves hypoxia induced dysfunctions in 3T3-L1 adipocytes by protecting mitochondria and down regulating inflammation. Biofactors 40:513–523.
125. Rabe K, Lehrke M, Parhofer KG, Broedl UC. 2008. Adipokines and insulin resistance. Mol Med 14:741–751.
126. Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, Sahebkar A. 2016. Treatment of non-alcoholic fatty liver disease with curcumin: A randomized placebo-controlled trial. Phytother Res 30:1540–1548.
127. Rajala MW, Obici S, Scherer PE, Rossetti L. 2003. Adipose-derived resistin and gut-derived resistin-like molecule-β selectively impair insulin action on glucose production. J Clin Invest 111:225–230.
128. Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L, Lazar MA. 2004. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 53:1937–1941.
129. Rea R, Donnelly R. 2004. Resistin: An adipocyte-derived hormone. Has it a role in diabetes and obesity? Diabetes Obes Metab 6:163–170.
130. Sahebkar A. 2010. Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril 94:e75–e76; author reply e77.
131. Sahebkar A. 2013. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors 39:197–208.
132. Sahebkar A. 2014a. Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol 11:123.
133. Sahebkar A. 2014b. Low-density lipoprotein is a potential target for curcumin: Novel mechanistic insights. Basic Clin Pharmacol Toxicol 114:437–438.
134. Sahebkar A. 2016. Curcumin: A natural multitarget treatment for pancreatic cancer. Integr Cancer Ther 15:333–334.
135. Sahebkar A, Cicero AF, Simental-Mendia LE, Aggarwal BB, Gupta SC. 2016. Curcumin downregulates human tumor necrosis factor-alpha levels: A systematic review and meta-analysis ofrandomized controlled trials. Pharmacol Res 107:234–242.
136. Sahebkar A, Henrotin Y. 2016. Analgesic efficacy and safety of curcuminoids in clinical practice: A systematic review and meta-analysis of randomized controlled trials. Pain Med 17:1192–1202.
137. Sahebkar A, Mohammadi A, Atabati A, Rahiman S, Tavallaie S, Iranshahi M, Akhlaghi S, Ferns GA, Ghayour-Mobarhan M. 2013. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 27:1883–1888.
138. Sahebkar A, Serban MC, Ursoniu S, Banach M. 2015. Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials. J Funct Foods 18:898–909.
139. Satoh H, Nguyen MA, Miles PD, Imamura T, Usui I, Olefsky JM. 2004. Adenovirus-mediated chronic “hyper-resistinemia” leads to in vivo insulin resistance in normal rats. J Clin Invest 114:224–231.
140. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S. 2001. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-γ action in humans. Diabetes 50:2199–2202.
141. Seo KI, Choi MS, Jung UJ, Kim HJ, Yeo J, Jeon SM, Lee MK. 2008. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res 52:995–1004.
142. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A. 2007. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. Biochem Pharmacol 73:1434–1445.
143. Sharma RA, Steward WP, Gescher AJ. 2007. Pharmacokinetics and pharmacodynamics of curcumineditor^editors. The molecular targets and therapeutic uses of curcumin in health and disease. NY, City: Springer. pp 453–470.
144. Shetty S, Kusminski CM, Scherer PE. 2009. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacological Sci 30:234–239.
145. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas P. 1998. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64:353–356.
146. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. 2005. Human resistin stimulates the pro-inflammatory cytokines TNF-α and IL-12 in macrophages by NF-κB-dependent pathway. Biochem Biophys Res Commun 334:1092–1101.
147. Siriwardhana N, Kalupahana NS, Cekanova M, LeMieux M, Greer B, Moustaid-Moussa N. 2013. Modulation of adipose tissue inflammation by bioactive food compounds. J Nutr Biochem 24:613–623.
148. Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM, Ramachandran A. 2003. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 26:3226–3229.
149. Snijder MB, Heine RJ, Seidell JC, Bouter LM, Stehouwer CD, Nijpels G, Funahashi T, Matsuzawa Y, Shimomura I, Dekker JM. 2006. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women the hoorn study. Diabetes Care 29:2498–2503.
150. Soetikno V, Sari FR, Veeraveedu PT, Thandavarayan RA, Harima M, Sukumaran V, Lakshmanan AP, Suzuki K, Kawachi H, Watanabe K. 2011. Curcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr Metab 8:35.
151. Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. 2003. Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228.
152. Srinivasan M. 1972. Effect of curcumin on blood sugar as seen in a diabetic subject. Indian J Med Sci 26:269–270.
153. Stastny J, Bienertova-Vasku J, Vasku A. 2012. Visfatin and its role in obesity development. Diabetes Metab Syndr 6:120–124.
154. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. 2001. The hormone resistin links obesity to diabetes. Nature 409:307–312.
155. Steppan CM, Lazar MA. 2004. The current biology of resistin. J Int Med 255:439–447.
156. Sun L-N, Yang Z-Y, Lv S-S, Liu X-C, Guan G-J, Liu G. 2014. Curcumin prevents diabetic nephropathy against inflammatory response via reversing caveolin-1 Tyr 14 phosphorylation influenced TLR4 activation. Int Immunopharmacol 23:236–246.
157. Suryanarayana P, Satyanarayana A, Balakrishna N, Kumar PU, Reddy GB. 2007. Effect of turmeric and curcumin on oxidative stress and antioxidant enzymes in streptozotocin-induced diabetic rat. Med Sci Monit 13:BR286–BR292.
158. Tang Y, Chen A. 2010a. Curcumin prevents leptin raising glucose levels in hepatic stellate cells by blocking translocation of glucose transporter-4 and increasing glucokinase. Br J Pharmacol 161:1137–1149.
159. Tang Y, Chen A. 2010b. Curcumin protects hepatic stellate cells against leptin-induced activation in vitro by accumulating intracellular lipids. Endocrinology 151:4168–4177.
160. Tang Y, Zheng S, Chen A. 2009. Curcumin eliminates leptin's effects on hepatic stellate cell activation via interrupting leptin signaling. Endocrinology 150:3011–3020.
161. Teymouri M, Pirro M, Johnston TP, Sahebkar A. 2017. Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: A review of chemistry, cellular, molecular, and preclinical features. Biofactors 43:331–346.
162. Thandavarayan RA, Watanabe K, Ma M, Veeraveedu PT, Gurusamy N, Palaniyandi SS, Zhang S, Muslin AJ, Kodama M, Aizawa Y. 2008. 14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy. Biochem Pharmacol 75:1797–1806.
163. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, Staiger H, Maerker E, Häring H, Stumvoll M. 2003. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52:239–243.
164. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, Vasseur F, Froguel P. 2003. Impaired multimerization of human adiponectin mutants associated with diabetes molecular structure and multimer formation of adiponectin. J Biol Chem 278:40352–40363.
165. Wang B, Wood IS, Trayhurn P. 2007. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflügers Arch Eur J Physiol 455:479–492.
166. Wang Y, Lam KS, Chan L, Chan KW, Lam JB, Lam MC, Hoo RC, Mak WW, Cooper GJ, Xu A. 2006. Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. Journal of Biological Chemistry 281:16391–16400.
167. Weisberg SP, Leibel R, Tortoriello DV. 2008a. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 149:3549–3558.
168. Weisberg SP, Leibel R, Tortoriello DV. 2008b. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 149:3549–3558.
169. Wellen KE, Hotamisligil GS. 2003. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112:1785–1788.
170. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. 2001. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935.
171. Wickenberg J, Ingemansson SL, Hlebowicz J. 2010. Effects of Curcuma longa (turmeric) on postprandial plasma glucose and insulin in healthy subjects. Nutr J 9:1.
172. Woo HM, Kang JH, Kawada T, Yoo H, Sung MK, Yu R. 2007. Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes. Life Sci. 80:926–931.
173. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946.
174. Yekollu SK, Thomas R, O'Sullivan B. 2011. Targeting curcusomes to inflammatory dendritic cells inhibits NF-κB and improves insulin resistance in obese mice. Diabetes 60:2928–2938.
175. Youn B-S, Yu K-Y, Park HJ, Lee NS, Min SS, Youn MY, Cho YM, Park YJ, Kim SY, Lee HK. 2004. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 89:150–156.
176. Yu Y, Hu S, Yan H. 2008a. The study of insulin resistance and leptin resistance on the model of simplicity obesity rats by curcumin. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine] 42:818–822.
177. Yu Y, Hu SK, Yan H. 2008b. The study of insulin resistance and leptin resistance on the model of simplicity obesity rats by curcumin. Zhonghua Yu f Ang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine] 42:818–822.
178. Yun Chen J-HL, Chang-Ping Li, Xiao-Lin Z, Min K. 2015. Effect of curcumin on Visfatin and Zinc-α2-glycoprotein expression in NAFLD in rats. 23:4005–4014.
179. Yun J-M, Jialal I, Devaraj S. 2011. Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin. J Nutr Biochem 22:450–458.
180. Zabihi NA, Pirro M, Johnston TP, Sahebkar A. 2017. Is there a role for curcumin supplementation in the treatment of non-alcoholic fatty liver disease? The data suggest yes. Curr Pharm Des 23:969–982.
181. Zhang D-w, Fu M, Gao S-H, Liu J-L. 2013. Curcumin and diabetes: A systematic review. Evid Based Complement Alternat Med 2013. https://doi.org/10.1155/2013/636053